RCUS
USDArcus Biosciences Inc. Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$19.700
Máximo
$20.500
Mínimo
$19.691
Volumen
0.41M
Fundamentos de la Empresa
Capitalización de Mercado
2.4B
Industria
Biotecnología
País
United States
Estadísticas de Negociación
Volumen Promedio
1.18M
Bolsa
NYQ
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune
Goldman Sachs Maintains Neutral on Arcus Biosciences, Raises Price Target to $16
Goldman Sachs analyst Salveen Richter maintains Arcus Biosciences with a Neutral and raises the price target from $14 to $16.
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $56
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences with a Buy and raises the price target from $54 to $56.
HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $28
HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences with a Buy and raises the price target from $24 to $28.
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
Casdatifan, a potential best-in-class HIF-2a inhibitor, demonstrated 12.2 months median progression-free survival (mPFS) and 18-month landmark PFS of 43% in a pooled analysis of 121 patients with late-line kidney
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $54
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences with a Buy and raises the price target from $47 to $54.
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study
First overall survival (OS) results from Arm A1 of the Phase 2 EDGE-Gastric study will be presented on October 18 at the European Society for Medical Oncology (ESMO) 2025 Congress These data support the ongoing
Acciones Relacionadas
CLFD
Clearfield Inc.
EP
Empire Petroleum Corporation
BHFAM
Brighthouse Financial Inc. Depositary shares each representing a 1/1000th Interest in a Share of 4.625% Non-Cumulative Preferred Stock Series D
SLNO
Soleno Therapeutics Inc.
ICFI
ICF International Inc.
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.